Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death.

Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH.

Cancer Immunol Res. 2017 Jun;5(6):493-502. doi: 10.1158/2326-6066.CIR-16-0216. Epub 2017 May 3.

PMID:
28468916
2.

Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma.

Pardee AD, Yano H, Weinstein AM, Ponce AA, Ethridge AD, Normolle DP, Vujanovic L, Mizejewski GJ, Watkins SC, Butterfield LH.

J Immunother Cancer. 2015 Jul 21;3:32. doi: 10.1186/s40425-015-0077-x. eCollection 2015.

3.

Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells.

Pardee AD, Shi J, Butterfield LH.

J Immunol. 2014 Dec 1;193(11):5723-32. doi: 10.4049/jimmunol.1400725. Epub 2014 Oct 29.

4.

Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH.

Oncoimmunology. 2012 May 1;1(3):287-357.

5.

Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.

Pardee AD, Butterfield LH.

Oncoimmunology. 2012 Jan 1;1(1):48-55.

6.

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ.

Cancer Res. 2010 Nov 15;70(22):9041-52. doi: 10.1158/0008-5472.CAN-10-1369. Epub 2010 Nov 2.

7.

Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment.

Qu Y, Chen L, Pardee AD, Taylor JL, Wesa AK, Storkus WJ.

J Immunol. 2010 Sep 1;185(5):2895-902. doi: 10.4049/jimmunol.1001294. Epub 2010 Jul 30.

8.

Integrating costimulatory agonists to optimize immune-based cancer therapies.

Pardee AD, Wesa AK, Storkus WJ.

Immunotherapy. 2009 Mar;1(2):249-64. doi: 10.2217/1750743X.1.2.249. Review.

9.

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.

Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ.

J Immunother. 2009 Oct;32(8):793-802. doi: 10.1097/CJI.0b013e3181acec1e.

10.

IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit.

Sasaki K, Pardee AD, Okada H, Storkus WJ.

Eur J Immunol. 2008 Oct;38(10):2865-73. doi: 10.1002/eji.200838334.

11.

CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth.

Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, Alber S, Watkins SC, Pardee AD, Wesa AK, Storkus WJ.

Cancer Res. 2008 Oct 1;68(19):8076-84. doi: 10.1158/0008-5472.CAN-08-0387.

12.

Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.

Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ.

J Immunol. 2008 Jul 1;181(1):104-8.

Supplemental Content

Loading ...
Support Center